TriangleNCT01266967 · OUTCOME
Number of Participants With Abnormal Echocardiograms (ECHO) at Weeks 4 and 12
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- NUMBER
- Unit
- participants
- Interval / dispersion
- Not reported
- Time frame
- Weeks (W) 4 and 12
What was measured
Echocardiograms (ECHO) were measured for all treated participants. An echocardiogram test gives information about the structure and function of the heart. LLN=lower limit of normal (determined by the institution).
Analysis population: ATS Population
Groups in this outcome
GSK2118436 150 mg: No Prior Local Therapy
Participants who received no prior local therapy for brain metastasis received GSK2118436 150 mg capsules either one hour before or 2 hours after a meal twice daily until evidence of disease progression, death, or unacceptable adverse events.
GSK2118436 150 mg: Prior Local Therapy
Participants who received prior local therapy for brain metastasis received GSK2118436 150 mg capsules either one hour before or 2 hours after a meal twice daily until evidence of disease progression, death, or unacceptable adverse events.
| Group | Source count |
|---|---|
| GSK2118436 150 mg: No Prior Local Therapy | 89 |
| GSK2118436 150 mg: Prior Local Therapy | 83 |
Reported measurements
W 4, Left ventricle (LV) ejection fraction < LLN
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| GSK2118436 150 mg: No Prior Local Therapy | 1 | Not reported | Not reported | Not reported | Not reported |
| GSK2118436 150 mg: Prior Local Therapy | 0 | Not reported | Not reported | Not reported | Not reported |
W 4, LV ejection fraction < normal
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| GSK2118436 150 mg: No Prior Local Therapy | 0 | Not reported | Not reported | Not reported | Not reported |
| GSK2118436 150 mg: Prior Local Therapy | 0 | Not reported | Not reported | Not reported | Not reported |
W 12, LV ejection fraction < LLN
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| GSK2118436 150 mg: No Prior Local Therapy | 0 | Not reported | Not reported | Not reported | Not reported |
| GSK2118436 150 mg: Prior Local Therapy | 0 | Not reported | Not reported | Not reported | Not reported |
W 12, LV ejection fraction < normal
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| GSK2118436 150 mg: No Prior Local Therapy | 1 | Not reported | Not reported | Not reported | Not reported |
| GSK2118436 150 mg: Prior Local Therapy | 0 | Not reported | Not reported | Not reported | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- value
- 1
- group Id
- OG001
- value
- 0
- title
- W 4, Left ventricle (LV) ejection fraction < LLN
- categories
- measurements
- group Id
- OG000
- value
- 0
- group Id
- OG001
- value
- 0
- title
- W 4, LV ejection fraction < normal
- categories
- measurements
- group Id
- OG000
- value
- 0
- group Id
- OG001
- value
- 0
- title
- W 12, LV ejection fraction < LLN
- categories
- measurements
- group Id
- OG000
- value
- 1
- group Id
- OG001
- value
- 0
- title
- W 12, LV ejection fraction < normal
- denoms
- counts
- group Id
- OG000
- value
- 89
- group Id
- OG001
- value
- 83
- units
- Participants
- description
- Echocardiograms (ECHO) were measured for all treated participants. An echocardiogram test gives information about the structure and function of the heart. LLN=lower limit of normal (determined by the institution).
- groups
- description
- Participants who received no prior local therapy for brain metastasis received GSK2118436 150 mg capsules either one hour before or 2 hours after a meal twice daily until evidence of disease progression, death, or unacceptable adverse events.
- id
- OG000
- title
- GSK2118436 150 mg: No Prior Local Therapy
- description
- Participants who received prior local therapy for brain metastasis received GSK2118436 150 mg capsules either one hour before or 2 hours after a meal twice daily until evidence of disease progression, death, or unacceptable adverse events.
- id
- OG001
- title
- GSK2118436 150 mg: Prior Local Therapy
- param Type
- NUMBER
- population Description
- ATS Population
- reporting Status
- POSTED
- time Frame
- Weeks (W) 4 and 12
- title
- Number of Participants With Abnormal Echocardiograms (ECHO) at Weeks 4 and 12
- type
- SECONDARY
- unit Of Measure
- participants
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice